Showing results (71-80 of 160) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|April 26, 2011
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitorElena Soto, Alexander Staab, Christiane Doege, et al.
The AAPS Journal|November 9, 2016
Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication RegimensDaniel Moj, Nina Hanke, Hannah Britz, et al.
Pharmaceutical Research|June 26, 2007
Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel BlockerGabriele Fliss, Alexander Staab, Christiane Tillmann, et al.
British Journal of Clinical Pharmacology|September 9, 2015
Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approachJens Markus Borghardt, Benjamin Weber, Alexander Staab, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2016
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniquesMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2017
An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitorMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 3, 2021
Novel models for the prediction of drug-gene interactionsDenise Türk, Laura Maria Fuhr, Fatima Zahra Marok, et al.
Thrombosis and Haemostasis|July 1, 2016
Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa studyJacqueline M L Halton, Thorsten Lehr, Lisa Cronin, et al.
Plos One|February 22, 2018
Population nutrikinetics of green tea extractCatharina Scholl, Anna Lepper, Thorsten Lehr, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2017
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysisNina Hanke, Michael Teifel, Daniel Moj, et al.
Pageof 16